混合18F-Florbetaben PET/MRI检测心脏淀粉样变性及预后参数
这项前瞻性探索性观察研究纳入21例确诊心脏淀粉样变性患者,采用18F-Florbetaben PET/MRI成像并随访至36个月,评估影像生物标志物对主要不良心血管事件(MACE)的预测价值。结果显示平均滞留指数(RI)是唯一在单变量和多变量分析中均显著的独立预后影像生物标志物(HR=4.02,95%CI 1.25-12.9,p<0.05),NT-proBNP仅在单变量分析中显著。AL型患者MACE发生率高于其他亚型。
要点
- 平均RI是MACE的唯一独立预后影像生物标志物(HR=4.02)。
- NT-proBNP仅在单变量分析中预测MACE,多变量不显著。
- AL-CA患者MACE发生率高于其他亚型。
核心结论
- 整合18F-Florbetaben PET/MR可实现心脏淀粉样变性的诊断、亚型区分和结局预测。
- 平均RI是MACE唯一显著且独立的预后影像生物标志物。
研究设计与样本
- 前瞻性探索性观察研究,纳入21例确诊心脏淀粉样变性患者,随访至36个月,报告MACE(NCT07154381)。
- 扫描由两名盲法核医学医师判读,评估平均滞留指数(RI)、T1 mapping/细胞外容积(ECV)及血清标志物与无MACE生存的关联。
主要发现
- 21例患者中14例(66.7%)报告MACE。
- 较高的平均RI是单变量和多变量分析中唯一显著的MACE预测影像生物标志物(HR=4.02,95%CI 1.25-12.9,p<0.05)。
- NT-proBNP在单变量分析中显著预测MACE,但多变量分析中不显著。
- AL-CA患者MACE发生率高于其他亚型患者。
关键数值与推荐
- 平均RI的HR=4.02(95%CI 1.25-12.9,p<0.05)为MACE独立预测因子。
临床怎么用
- 18F-Florbetaben PET/MRI可用于心脏淀粉样变性的诊断、亚型区分及预后评估。
- 平均RI可作为MACE风险分层的独立影像生物标志物。
局限性
- 探索性研究样本量小(21例),结论需更大规模前瞻性研究验证。
- 未来需研究对患者管理和风险评估的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Positron emission tomography (PET) with amyloid-binding tracers was shown to have high sensitivity for the detection of both transthyretin (ATTR) and light-chain (AL) cardiac amyloidosis (CA). Recent studies describe prognostic value of imaging biomarkers from bone scintigraphy and 18F-Florbetapir. The aim of this study was to evaluate the value of imaging biomarkers from 18F-Florbetaben PET, cardiac magnetic resonance (CMR), and echocardiography imaging for prediction of major adverse cardiac events (MACE) in comparison to serum biomarkers in patients with different types of CA. METHODS: Patients who underwent cardiac 18F-Florbetaben PET/MRI were prospectively enrolled and received clinical follow-up for up to 36 months and MACE were reported (NCT07154381). Scans were reported by two blinded, nuclear medicine physicians. Imaging biomarkers including average retention index (RI), T1 mapping/ extracellular volume (ECV) and serological markers were estimated and their association with MACE free survival was analyzed. RESULTS: Twenty-one patients with confirmed CA were enrolled. MACEs were reported in 14 of 21 patients (66.7%). Higher average RI was the only imaging biomarker that was a significant predictor for MACE in uni- and multivariate analysis (HR = 4.02, 95%CI: 1.25-12.9, p < 0.05). N-terminal pro-B-type natriuretic peptide (NT-proBNP) was a significant predictor in uni- but not in multivariate analysis. Patients with AL-CA showed a higher rate of MACE than patients with other subtypes. CONCLUSION: Integrated 18F-Florbetaben PET/MR allows diagnosis, subtype differentiation and outcome predication of CA. The average RI was the only significant and independent prognostic imaging biomarker of MACE. Future prospective studies are warranted to investigate benefits for patient management and risk assessment in larger cohorts.
引用
- Kessler L, Tonscheidt W, Nassenstein K, et al. Prognostic parameters and detection of cardiac amyloidosis with hybrid 18F-Florbetaben-PET/MRI: an exploratory observational study. Eur J Nucl Med Mol Imaging. 2026. PMID: 41653266. doi:10.1007/s00259-025-07733-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。